---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-22-012903"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2022-12-30T23:59:59+00:00"
generated_at: "2026-06-20T21:44:57.131416+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Adamis receives Nasdaq delisting notice for bid-price non-compliance; plans appeal

## Summary
- Nasdaq Staff issued delisting determination on Dec 28, 2022, for failure to meet minimum bid price under Rule 5550(a)(2).
- Company had two 180-day grace periods through Dec 27, 2022, but did not regain compliance.
- Adamis will timely request a hearing before the Nasdaq Hearings Panel, which stays delisting pending decision.
- If delisted, shares would be eligible to trade on the OTC Markets platform.
- No assurance that the Panel will grant continued listing or additional compliance extension.

## SEC filing metadata
- accession: 0001387131-22-012903
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2022-12-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713122012903/0001387131-22-012903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713122012903/admp-8k_122822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-22-012903
- JSON: https://secwatch.observer/filing/0001387131-22-012903.json
- Plain text: https://secwatch.observer/filing/0001387131-22-012903.txt

## Key facts
- Listing & Compliance Notices
  DMK PHARMACEUTICALS Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 28, 2022, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) as of December 27, 2022, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any furth
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713122012903/0001387131-22-012903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.